Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1611 1626 1641 1658
This examiner grants 44% of resolved cases
Judith Marie Kamm is an examiner in Tech Center 1600 and Art Unit 1611, with 61 resolved cases. The data shows an allowance rate pct of 44.3 and a median days to allowance of 1429. These 61 resolved cases provide a statistical basis for understanding the examiner's approach. The 44.3 percent allowance rate indicates the frequency of granted patents for applications assigned to this examiner in Art Unit 1611.
The interview lift pct of 56.0 is a significant figure, indicating that interviews are a highly effective tool for increasing the probability of allowance. This 56.0 percent lift suggests that direct communication is a key strategy for practitioners. The 1429 days to allowance establishes the expected timeline for reaching an outcome. The 44.3 percent allowance rate and the 56.0 percent interview lift are the primary metrics for strategic planning. The 1429 days to allowance serves as the benchmark for pendency.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18618262 | LIQUID EMBOLIC MATERIALS | Final Rejection | Boston Scientific Scimed, Inc. |
| 18398730 | Lipid Compositions and Methods for Delivery to Immune Cells | Non-Final OA | LIFE TECHNOLOGIES CORPORATION |
| 19039128 | HAIR CARE COMPOSITION | Non-Final OA | The Procter & Gamble Company |
| 18013508 | GSK3 INHIBITOR-LOADED NANO FORMULATIONS AS A CANCER IMMUNOTHERAPEUTIC | Final Rejection | The Regents of the University of California |
| 18719997 | Composition | Final Rejection | Syngenta Crop Protection AG |
| 18039554 | COMPOSITIONS COMPRISING MESOSULFURON-METHYL AND TEHP | Non-Final OA | BAYER AKTIENGESELLSCHAFT |
| 18569924 | MODIFICATION OF PLANT MESSENGER PACKS | Non-Final OA | Flagship Pioneering Innovations VI, LLC |
| 17972972 | PLASTICIZERS TO IMPROVE RELEASE PERFORMANCE OF AMORPHOUS SOLID DISPERSIONS | Final Rejection | Purdue Research Foundation |
| 17233594 | SKELETAL MUSCLE REGENERATION IN VOLUMETRIC MUSCLE LOSS USING BIOMIMETIC GLYCOSAMINOGLYCAN-BASED HYDROGEL | Non-Final OA | Purdue Research Foundation |
| 18041618 | NANOPARTICULATE SYSTEM FOR TREATING ORAL CANCER | Final Rejection | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 18962927 | Personal Care Products | Non-Final OA | Colgate-Palmolive Company |
| 18796471 | RED COLORANT FREE OF COCHINEAL RED AND COMPOSITIONS COMPRISING THE SAME | Non-Final OA | Conopco, Inc., d/b/a UNILEVER |
| 19067198 | TOPICAL ADMINISTRATION TO THE ORAL CAVITY | Final Rejection | CMPD Licensing, LLC |
| 19067153 | TOPICAL ADMINISTRATION TO THE ORAL CAVITY | Final Rejection | CMPD Licensing, LLC |
| 18799390 | NOVEL NANOPARTICLES OF ANTIRETROVIRAL DRUGS, THEIR PREPARATION AND THEIR USE FOR THE TREATMENT OF VIRAL INFECTIONS | Non-Final OA | UNIVERSITE PARIS-SACLAY |
| 18018205 | TRANS-CROCETIN COMPOSITIONS AND TREATMENT REGIMENS | Final Rejection | L.E.A.F. HOLDINGS GROUP LLC |
| 18873041 | STORAGE STABILIZATION AGENT FOR STABILIZING AQUEOUS COMPOSITIONS, PROCESS FOR STABILIZING AND USES THEREOF | Non-Final OA | Omya International AG |
| 18950187 | THUMBTACK NEEDLE DRESSING FOR HEMOSTASIS AFTER OPERATION | Non-Final OA | Shanghai Sixth People's Hospital |
| 18031583 | COMPOSITION | Non-Final OA | Givaudan SA |
| 17786971 | RECTAL DELIVERY OF MESSENGER RNA | Non-Final OA | Translate Bio, Inc |
| 18833384 | New Coolants, and Preparations Containing Same | Non-Final OA | Symrise AG |
| 18301051 | Compositions Comprising (Bio)-Alkanediols with Antimicrobials for Product Protection | Non-Final OA | Symrise AG |
| 18009295 | Compositions Comprising (Bio)-Alkanediols with Antimicrobials for Product Protection | Final Rejection | Symrise AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy